Virginia Li's Archive

Virginia is currently a research assistant at the University of Chicago, where she studies brain development in children acquiring early language and reading skills. She recently received her B.A. in Biology from Cornell University and hopes to pursue a career in science journalism. Outside of work, she enjoys cooking, photography, and teaching gymnastics. Virginia joined The Myeloma Beacon in November 2011.

Virginia Li has written 78 article(s) .

[ by and | Dec 24, 2013 11:47 am | One Comment ]
Filanesib (ARRY-520) Continues To Show Promise In Heavily Pretreated Multiple Myeloma Patients (ASH 2013)

Results from three clinical trials involving the inves­ti­ga­tional drug filanesib were presented at the American Society of Hematology (ASH) annual meeting earlier this month.

The trials evaluated the efficacy of filanesib (ARRY-520) alone and in com­bi­na­tion with other agents as potential treat­ments for re­lapsed and refractory multiple myeloma patients.

Overall, the trial results presented at ASH con­firm existing impressions of filanesib as a promising potential myeloma ther­apy.

Results of a Phase 2 trial of filanesib with or …

Tags: , , , , , , , , ,
Read the full story »
[ by and | Dec 11, 2013 6:20 pm | Comments Off ]
ASH 2013 Multiple Myeloma Update - Day Three: Afternoon Oral Sessions

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treat­ment options for newly diag­nosed, re­lapsed and …

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Read the full story »
[ by and | Jul 8, 2013 3:12 pm | 3 Comments ]
Researchers Develop Model To Identify Myeloma Patients With MGUS-Like Disease

Spanish researchers recently developed a new model based on a technique called multiparameter flow cytometry that can identify newly diagnosed multiple myeloma patients with disease profiles similar to those of patients with the myeloma precursor disease monoclonal gammopathy of undetermined significance.

The set of myeloma patients identified as having disease similar to monoclonal gammopathy of undetermined significance (MGUS) had better disease status at diagnosis and better long-term survival than other newly diagnosed myeloma patients, regardless of the depth of their …

Tags: , , , ,
Read the full story »
[ by | Jun 21, 2013 5:22 pm | Comments Off ]
Two New Studies Investigate The Significance Of Minimal Residual Disease In Multiple Myeloma

The results of two recent European studies provide new insights into minimal residual disease detection and its potential value in the treat­ment of multiple myeloma.

The first study, carried out in Spain, used two different methods to detect mini­mal residual disease (MRD) in myeloma patients.  The study found that the two methods led to similar results, and that MRD levels may be a better predictor of patient prognosis than traditional measures of treat­ment response.

The second study was conducted by …

Tags: , , , , , , , ,
Read the full story »
[ by | Jun 5, 2013 7:43 am | 2 Comments ]
ASCO 2013 Multiple Myeloma Update – Day Four: Oral Presentations

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.

Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that in­cluded eight talks about im­por­tant new myeloma-related research. A poster session in the afternoon in­cluded several posters about myeloma-related research.

This article summarizes the most im­por­tant findings from Monday's oral pre­sen­ta­tion session. A later article will cover the findings from the after­noon …

Tags: , , , , , , , , , , , , , , , , ,
Read the full story »
[ by and | Jun 3, 2013 9:27 pm | One Comment ]
ASCO 2013 Multiple Myeloma Update – Day Three: Poster Presentations

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.

Sunday started with a poster session in which im­por­tant new re­search findings were summarized on posters dis­played throughout a large conference hall.

The stud­ies pre­sented during the session were on a wide variety of myeloma-related topics, in­clud­ing new treat­ments being devel­oped for myeloma, cur­rently used regi­mens, smol­der­ing mul­ti­ple myeloma, and findings on initial ther­apy.

Some of the …

Tags: , , , , , , , , , , , , , , ,
Read the full story »
[ by | May 17, 2013 5:22 pm | Comments Off ]
Novel Agents Followed By Repeat Transplantation May Be Effective For Relapsed Myeloma

Results from a recent retrospective study conducted in Germany suggest that treatment with novel agents followed by an autologous stem cell transplant may be an effective and safe salvage therapy for relapsed mul­tiple myeloma patients who previously received a transplant.

The study investigators believe that this course of treatment could po­ten­tial­ly "serve as a bridge" to a late donor transplant in certain patients.

However, the researchers point out that many of the patients included in the analysis did not receive …

Tags: , , ,
Read the full story »